OR WAIT null SECS
© 2023 MJH Life Sciences and BioPharm International. All rights reserved.
© 2023 MJH Life Sciences™ and BioPharm International. All rights reserved.
Manufacturers face the challenge of meeting growing demand for personalized biopharmaceuticals.
Despite many development challenges, stable producer cell lines show real promise.
CPC presents a green alternative to chromatography that supports sustainable operations.
Experts outline the benefits of single-use consumables relative to traditional approaches.
Considering the differences between small- and large-molecule drug products can help determine analytical testing methods for E&L.
September 13, 2023
Rentschler Biopharma’s ATMP business can now offer its full range of services for the clinical supply of AAV, including bioprocess and analytical development through to cGMP manufacturing at the Stevenage facility in the UK.
Despite the successes that have already been achieved with emerging therapy development and manufacturing, companies are still facing numerous challenges.
Seagen will be responsible for conjugating these degraders to antibodies to make DACs and advancing these DAC drug candidates through preclinical and clinical development and commercialization.
September 12, 2023
The results showed that PathoQuest’s proprietary NGS approach is an effective, more robust replacement to in vivo adventitious virus testing of cell substrates used in the production of biologics, like monoclonal antibodies, vaccines, cell, and gene therapies.
September 11, 2023
The agreement states that Orbit will implement its bead-based peptide display engine to discover peptide leads specific to targets related to specific tumors.
September 08, 2023
The new policy will require trading partners to supply, accept, and manage all documentation of product and ownership of prescription drugs electronically.
September 07, 2023
Illumina’s new solutions center in Bengaluru, India, will expand access to genomics in the country.
Optibrium announced on Aug. 31, 2023 the acquisition of BioPharmics to further expand the 3D drug design and modelling offering and to focus on research and development and application science.
September 06, 2023
Further expansions of the pharmaceutical development and manufacturing services of ten23 are happening at the BASE and VIVA facilities to continue to support complex sterile product development, testing, and manufacturing.
September 05, 2023
Novo Nordisk receives the full rights to develop and commercialize the lead program.
Both companies have a focus to developing and commercializing treatments for rare diseases with a strong focus on patients and supporting communities with little to no existing therapeutic options.
September 02, 2023
Nanoparticles offer the potential for a safer, more effective method of drug delivery to the patient.